Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30919368 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL8445003 | 0.87 | MAPT (0.78) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL7820954 | 0.84 | KMT2A (0.71) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL29356341 | 0.78 | MAPT (0.63) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL16323481 | 0.78 | MAPT (0.63) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL20869701 | 0.75 | MAPT (0.60) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL14200808 | 0.72 | MAPT (0.57) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL13196135 | 0.72 | KDM4E (0.56) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL460367 | 0.70 | MAOA (0.56) | MAPTMEN1KMT2AKDM4EHSP90AA1 | |
| SCHEMBL68338 | 0.65 | TTR (0.64) | MAPTMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975032-B2 | Medicament for liver regeneration and for treatment of liver failure | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2024-05-07 | — | — | US | disclosed |
| US-20190099453-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2019-04-04 | — | — | US | disclosed |
| US-20190091265-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-10188682-B2 | Medicament for liver regeneration and for treatment of liver failure | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-01-29 | — | — | US | disclosed |
| EP-3192870-B1 | CULTIVATED HEPATOCYTE FOR BLOOD PURIFICATION | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3192870-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-2694652-B1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9273012-B2 | Facile preparation of 4-substituted quinazolines and related heterocycles | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160022742-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20160022742-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20140141510-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140141510-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-2694652-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| US-20120283436-A1 | FACILE PREPARATION OF 4-SUBSTITUTED QUINAZOLINES AND RELATED HETEROCYCLES | THE UNIVERSITY OF HOUSTON (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012136859-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2012-10-11 | — | — | WO | disclosed |
| EP-0483249-B1 | METHOD OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS | OSI PHARM INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6376175-B1 | CONTACTING CELL WHICH IS CAPABLE OF EXPRESSING GENE WITH AMOUNT OF MOLECULE EFFECTIVE TO TRANSCRIPTIONALLY MODULATE EXPRESSION OF GENE AND THEREBY AFFECT LEVEL OF PROTEIN ENCODED BY GENE WHICH IS EXPRESSED BY CELL | OSI PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| US-5861398-A | Benzoperimidine-carboxylic acids and derivatives thereof | ALANEX CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| WO-1998008821-A1 | BENZOPERIMIDINE-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | AGOURON ACQUISITION CORP. (US) | 1998-03-05 | — | — | WO | disclosed |
| US-5665543-A | Method of discovering chemicals capable of functioning as gene expression modulators | ONCOGENE SCIENCE, INC. (US) | 1997-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022742-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | PYGL, HNF4A, ATF1 | MAPT 4517/4885MEN1 3939/4885KMT2A 2105/4885 |
| US-20140141510-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | PYGL, HNF4A, ATF1 | MAPT 4517/4885MEN1 3939/4885KMT2A 2105/4885 |
| US-20190091265-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | PYGL, HNF4A, ATF1 | MAPT 4517/4885MEN1 3939/4885KMT2A 2105/4885 |
| US-10188682-B2 | Medicament for liver regeneration and for treatment of liver failure | PYGL, HNF4A, ATF1 | MAPT 4517/4885MEN1 3939/4885KMT2A 2105/4885 |
| US-20190099453-A1 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE | PYGL, HNF4A, ATF1 | MAPT 4517/4885MEN1 3939/4885KMT2A 2105/4885 |
| US-11975032-B2 | Medicament for liver regeneration and for treatment of liver failure | PYGL, HNF4A, ATF1 | MAPT 4517/4885MEN1 3939/4885KMT2A 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.